Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Collections
    • Subjects A-Z
    • Residents & Fellows
    • Patient Pages
  • Podcast
  • CME
    • Article CME
    • Podcast CME
  • About
    • About the Journals
    • Contact Us
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Collections
    • Subjects A-Z
    • Residents & Fellows
    • Patient Pages
  • Podcast
  • CME
    • Article CME
    • Podcast CME
  • About
    • About the Journals
    • Contact Us
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Practice Current

User menu

  • Subscribe
  • My alerts
  • Log in

Search

  • Advanced search
Neurology Clinical Practice
Home
A peer-reviewed clinical neurology journal for the practicing neurologist
  • Subscribe
  • My alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Practice Current

Share

June 2018; 8 (3) The Nerve! Readers Speak

Reader response: Pimavanserin: A novel therapeutic option for Parkinson disease psychosis

Abigail C. Keys Lawler, Yasar Torres-Yaghi, Fahd Amjad, Charbel Moussa, Fernando Pagan
First published June 11, 2018, DOI: https://doi.org/10.1212/CPJ.0000000000000467
Abigail C. Keys Lawler
Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasar Torres-Yaghi
Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fahd Amjad
Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charbel Moussa
Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernando Pagan
Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Reader response: Pimavanserin: A novel therapeutic option for Parkinson disease psychosis
Abigail C. Keys Lawler, Yasar Torres-Yaghi, Fahd Amjad, Charbel Moussa, Fernando Pagan
Neurol Clin Pract Jun 2018, 8 (3) 175; DOI: 10.1212/CPJ.0000000000000467

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Comment

Downloads
68

Share

  • Article
  • Info
Loading

Hawkins and Berman1 acknowledge limitations to current therapeutic approaches (including medication costs), but underestimate potential negative effects of Parkinson disease psychosis (PDP) on the patient, caregiver, and health care system. PDP may be a harbinger of increased risk of morbidity and mortality, as well as portend admittance to a long-term care facility; these factors ultimately correlate with a surmountable burden on the system and higher cost to the patient over time.

The authors suggest that pimavanserin should be used as a second-line agent to an initial trial of low-dose quetiapine. An efficacious low dose is unlikely, and even at a low dose quetiapine can cause harmful side effects.2 Early use of pimavanserin may be more cost-effective and result in no worsening of motor functions and no reduction in dopaminergic agents.3 Atypical antipsychotics should be second line to pimavanserin when Parkinson disease dementia is not sufficiently controlled.

Pimavanserin should be used as a first-line agent for the treatment of PDP and treatment should be started at symptom onset since PDP progression can be unpredictable. We agree with the Food and Drug Administration's indication for the use of pimavanserin4 given its efficacy data and safety profile and considering the broad side effect profile of the alternative antipsychotic medications.

Footnotes

  • Author disclosures are available upon request (ncpjournal{at}neurology.org).

  • See response

  • © 2018 American Academy of Neurology

References

  1. 1.↵
    1. Hawkins T,
    2. Berman BD
    . Pimavanserin: a novel therapeutic option for Parkinson disease psychosis. Neurol Clin Pract 2017;7:157–162.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Ballanger B,
    2. Strafella AP,
    3. van Eimeren T, et al
    . Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010;67:416–421.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Cummings J,
    2. Isaacson S,
    3. Mills R, et al
    . Pimavanserin for patients with Parkinson's disease psychosis: a randomized, placebo-controlled phase 3 trial. Lancet 2014;383:533–540.
    OpenUrlCrossRefPubMed
  4. 4.↵
    FDA approves first drug to treat hallucinations and delusions associated with Parkinson's disease. Available at: fda.gov/newsevents/newsroom/pressannouncements/ucm498442.htm. Accessed November 8, 2017.
View Abstract

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.cp.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on The Nerve!

Compose comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All contributors, besides the first/corresponding author, must complete a separate The Nerve! Submission Form and provide via email to the editorial office before comments can be posted.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Footnotes
    • References
  • Info

Related Articles

  • Author response: Pimavanserin: A novel therapeutic option for Parkinson disease psychosis

Alert Me

  • Alert me when this article is cited
  • Alert me if a correction is posted
  • Alert me when eletters are published
Advertisement
Neurology: Clinical Practice: 9 (1)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Clinical Practice |  Print ISSN: 2163-0402
Online ISSN: 2163-0933

© 2019 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise